Physician profile
Frederick Boltz
NPI 1003907890
$7,847.48
in general payments reported to CMS, 2019-2025
56 companies · $1,250 in 2025
The $1,250 reported for 2025 was more than what 90% of providers received nationally.
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $1,990 · 2020: $864 · 2021: $1,313 · 2022: $1,054 · 2023: $508 · 2024: $870 · 2025: $1,250.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $2,607 · Compensation For Services Other Than Consulting, Including Serving As Faculty Or As A Speaker At A Venue Other Than A Continuing Education Program: $20.39.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $2,607.29 |
| Compensation For Services Other Than Consulting, Including Serving As Faculty Or As A Speaker At A Venue Other Than A Continuing Education Program | $20.39 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Abbvie INC. | $798.80 | 2019-2025 | Qulipta, Ubrelvy, Botox |
| Genzyme Corporation | $708.84 | 2019-2023 | |
| Emd Serono, INC. | $549.74 | 2019-2025 | Mavenclad |
| Amgen INC. | $546.85 | 2019-2025 | Uplizna, Aimovig |
| Novartis Pharmaceuticals Corporation | $526.21 | 2019-2025 | |
| Ucb, INC. | $330.29 | 2019-2025 | Zilbrysq, Rystiggo |
| Acadia Pharmaceuticals INC | $297.98 | 2019-2024 | Nuplazid |
| Teva Pharmaceuticals USA, INC. | $292.79 | 2019-2025 | Austedo, Austedo Xr |
| Lilly USA, LLC | $262.47 | 2019-2025 | Kisunla |
| Lundbeck LLC | $249.77 | 2019-2025 | Vyepti |
| Celgene Corporation | $237.01 | 2020-2024 | Zeposia |
| Genentech USA, INC. | $221.53 | 2019-2025 | Ocrevus Zunovo |
| Alexion Pharmaceuticals, INC. | $190.93 | 2020-2025 | Ultomiris |
| Mdd US Operations, LLC | $176.59 | 2019-2025 | Apokyn, Apokyn |
| Takeda Pharmaceuticals U.S.A., INC. | $140.52 | 2022-2025 | Hyqvia |
Show all 56 companies
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Frederick Boltz listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.